New Efficacy Results on the use of Effaclar H Iso-Biome care and cleanser in doctors’ real practice

  • 5min
  • Mar. 2025
  • Supported by
  • La Roche-Posay
In our recent observational study, we aimed to investigate the way healthcare professionals prescribe Effaclar H ISO-BIOME care and cleansing foaming gel as an adjuvant to over-drying treatments in moderate to severe cases. This study was held in 2 continents and the results proved Effaclar H ISO-BIOME routine ultimate efficacy in acne prone skin management.

Effaclar H ISO-BIOME routine improves the symptoms felt by the patients in adjunct to prescribed treatments.

Effaclar H Iso-biome

REFERENCE:
*p<0,001
Observational study, Effaclar H Iso-biome care & cleanser, 2061 patients, mild to severe acne, 1/day or 2/day as prescribed by the Dermatologists, 3 months


Effaclar H ISO-BIOME Routine high tolerability rates assessed by patients and derms.

Effaclar H Iso-biome

REFERENCE:
*p<0,001
Observational study, Effaclar H Iso-biome care & cleanser, 2061 patients, mild to severe acne, 1/day or 2/day as prescribed by the Dermatologists, 3 months


Effaclar H ISO-BIOME routine improves the burden of acne on patients’ quality of life.

Effaclar H Iso-biome+

REFERENCE:
*p<0,001
Observational study, Effaclar H Iso-biome care & cleanser, 2061 patients, mild to severe acne, 1/day or 2/day as prescribed by the Dermatologists, 3 months CADI = Cardiff Acne Disability Index is a short five-item questionnaire to assess QOL